SRPT Annual Accounts Receivable
$400.33 M
+$185.70 M+86.52%
31 December 2023
Summary:
As of January 22, 2025, SRPT annual accounts receivable is $400.33 million, with the most recent change of +$185.70 million (+86.52%) on December 31, 2023. During the last 3 years, it has risen by +$299.46 million (+296.87%). SRPT annual accounts receivable is now at all-time high.SRPT Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Quarterly Accounts Receivable
$434.52 M
+$74.53 M+20.70%
30 September 2024
Summary:
As of January 22, 2025, SRPT quarterly accounts receivable is $434.52 million, with the most recent change of +$74.53 million (+20.70%) on September 30, 2024. Over the past year, it has increased by +$34.20 million (+8.54%). SRPT quarterly accounts receivable is now at all-time high.SRPT Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +86.5% | +8.5% |
| 3 y3 years | +296.9% | +115.6% |
| 5 y5 years | +729.7% | +115.6% |
SRPT Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +161.7% | at high | +184.0% |
| 5 y | 5-year | at high | +342.8% | at high | +383.0% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Sarepta Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $434.52 M(+20.7%) |
| June 2024 | - | $360.00 M(-5.0%) |
| Mar 2024 | - | $378.81 M(-5.4%) |
| Dec 2023 | $400.33 M(+86.5%) | $400.33 M(+25.6%) |
| Sept 2023 | - | $318.86 M(+34.6%) |
| June 2023 | - | $236.81 M(+5.8%) |
| Mar 2023 | - | $223.84 M(+4.3%) |
| Dec 2022 | $214.63 M(+40.3%) | $214.63 M(+6.5%) |
| Sept 2022 | - | $201.51 M(-1.2%) |
| June 2022 | - | $203.85 M(+14.4%) |
| Mar 2022 | - | $178.19 M(+16.5%) |
| Dec 2021 | $152.99 M(+51.7%) | $152.99 M(+2.5%) |
| Sept 2021 | - | $149.32 M(+17.5%) |
| June 2021 | - | $127.05 M(+7.9%) |
| Mar 2021 | - | $117.73 M(+16.7%) |
| Dec 2020 | $100.87 M(+11.6%) | $100.87 M(-3.5%) |
| Sept 2020 | - | $104.49 M(+10.3%) |
| June 2020 | - | $94.69 M(+5.3%) |
| Mar 2020 | - | $89.96 M(-0.5%) |
| Dec 2019 | $90.41 M(+87.4%) | $90.41 M(+34.4%) |
| Sept 2019 | - | $67.26 M(+19.7%) |
| June 2019 | - | $56.19 M(+13.0%) |
| Mar 2019 | - | $49.72 M(+3.0%) |
| Dec 2018 | $48.25 M(+69.1%) | $48.25 M(+0.9%) |
| Sept 2018 | - | $47.81 M(+13.7%) |
| June 2018 | - | $42.06 M(+8.1%) |
| Mar 2018 | - | $38.92 M(+36.4%) |
| Dec 2017 | $28.54 M(+445.9%) | $28.54 M(+15.3%) |
| Sept 2017 | - | $24.75 M(+39.1%) |
| June 2017 | - | $17.79 M(+44.9%) |
| Mar 2017 | - | $12.28 M(+134.9%) |
| Dec 2016 | $5.23 M(+31.5%) | $5.23 M(+31.2%) |
| Sept 2016 | - | $3.99 M(+0.1%) |
| June 2016 | - | $3.98 M(-0.2%) |
| Mar 2016 | - | $3.99 M(+0.3%) |
| Dec 2015 | $3.98 M | $3.98 M(+45.5%) |
| Sept 2015 | - | $2.73 M(+13.1%) |
| June 2015 | - | $2.42 M(0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $2.42 M(0.0%) |
| Dec 2014 | $2.42 M(-31.6%) | $2.42 M(-28.1%) |
| Sept 2014 | - | $3.36 M(-35.7%) |
| June 2014 | - | $5.23 M(-33.4%) |
| Mar 2014 | - | $7.85 M(+122.4%) |
| Dec 2013 | $3.53 M(-25.1%) | $3.53 M(-47.5%) |
| Sept 2013 | - | $6.72 M(+77.4%) |
| June 2013 | - | $3.79 M(-33.0%) |
| Mar 2013 | - | $5.65 M(+19.9%) |
| Dec 2012 | $4.71 M(+29.7%) | $4.71 M(+90.5%) |
| Sept 2012 | - | $2.47 M(-65.5%) |
| June 2012 | - | $7.18 M(+39.8%) |
| Mar 2012 | - | $5.13 M(+41.3%) |
| Dec 2011 | $3.63 M(+12.7%) | $3.63 M(-14.9%) |
| Sept 2011 | - | $4.27 M(-60.8%) |
| June 2011 | - | $10.89 M(-19.8%) |
| Mar 2011 | - | $13.58 M(+321.1%) |
| Dec 2010 | $3.22 M(+54.6%) | $3.22 M(-38.5%) |
| Sept 2010 | - | $5.24 M(+143.4%) |
| June 2010 | - | $2.15 M(+30.6%) |
| Mar 2010 | - | $1.65 M(-21.0%) |
| Dec 2009 | $2.08 M(-58.1%) | $2.08 M(-63.2%) |
| Sept 2009 | - | $5.67 M(+68.8%) |
| June 2009 | - | $3.36 M(+7.5%) |
| Mar 2009 | - | $3.13 M(-37.1%) |
| Dec 2008 | $4.97 M(+73.2%) | $4.97 M(+21.9%) |
| Sept 2008 | - | $4.08 M(+52.9%) |
| June 2008 | - | $2.67 M(-34.2%) |
| Mar 2008 | - | $4.05 M(+41.2%) |
| Dec 2007 | $2.87 M(+5472.4%) | $2.87 M(+63.9%) |
| Sept 2007 | - | $1.75 M(+56.4%) |
| June 2007 | - | $1.12 M(+102.9%) |
| Mar 2007 | - | $551.80 K(+971.5%) |
| Dec 2006 | $51.50 K(-95.8%) | $51.50 K(-16.0%) |
| Sept 2006 | - | $61.30 K(+38.1%) |
| June 2006 | - | $44.40 K(-94.7%) |
| Mar 2006 | - | $840.20 K(-32.0%) |
| Dec 2005 | $1.24 M | $1.24 M |
FAQ
- What is Sarepta Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual accounts receivable year-on-year change?
- What is Sarepta Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly accounts receivable year-on-year change?
What is Sarepta Therapeutics annual accounts receivable?
The current annual accounts receivable of SRPT is $400.33 M
What is the all time high annual accounts receivable for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual accounts receivable is $400.33 M
What is Sarepta Therapeutics annual accounts receivable year-on-year change?
Over the past year, SRPT annual accounts receivable has changed by +$185.70 M (+86.52%)
What is Sarepta Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of SRPT is $434.52 M
What is the all time high quarterly accounts receivable for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly accounts receivable is $434.52 M
What is Sarepta Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, SRPT quarterly accounts receivable has changed by +$34.20 M (+8.54%)